Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TSLP Kurv Yield Premium Strategy Tesla (TSLA) ETF

盘前交易 12-23 05:10:37 EST

32.42

+0.04

+0.11%

最高32.42	最低31.66	成交量6,098
今开31.66	昨收32.38	日振幅2.34%
总市值940.13万	流通市值940.13万	总股本29.00万
成交额19.72万	换手率2.10%	流通股本29.00万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","latestPrice":32.4183,"timestamp":1734727936234,"preClose":32.3821,"halted":0,"volume":6098,"delay":0,"floatShares":290000,"shares":290000,"eps":0,"marketStatus":"盘前交易","marketStatusCode":1,"change":0.0362,"latestTime":"12-23 05:10:37 EST","open":31.66,"high":32.4183,"low":31.66,"amount":197233.120494,"amplitude":0.023417,"askPrice":51,"askSize":200,"bidPrice":26.53,"bidSize":21,"shortable":3,"etf":1,"ttmEps":0,"exchange":"AMEX","tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734964200000},"adr":0,"adjPreClose":31.8801,"sharesOutstanding":290000,"nav":32.37,"aum":9387300,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":32.27,"preClose":31.8801,"latestTime":"16:56 EST","volume":16,"amount":522.03,"timestamp":1734731776039},"volumeRatio":0.4314602310981233,"impliedVol":0.0441,"impliedVolPercentile":0.0802},"requestUrl":"/m/hq/s/TSLP","defaultTab":"news","newsList":[{"id":"2489283889","title":"中国生物制药、博奥信授出TQC2731权益 首付款约4000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2489283889","media":"中国网财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2489283889?lang=zh_cn&edition=full","pubTime":"2024-12-06 19:18","pubTimestamp":1733483880,"startTime":"0","endTime":"0","summary":"中国网财经12月6日讯 中国生物制药昨日宣布，公司和博奥信生物技术 有限公司就联合开发的TSLP单克隆抗体BSI-045B与Aclaris Therapeutics, Inc.达成全球合作协议。根据协议，Aclaris Therapeutics同意承担约4000万美元首付款，部分开发成本和药物产品材料费用，9亿美元的研发及销售里程碑付款。资料显示，BSI-045B是一款靶向胸腺基质淋巴细胞生成素的人源化单克隆抗体，可以阻止TSLP靶向的免疫细胞释放促炎细胞因子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206192254a1d9068c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241206192254a1d9068c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TSLP","BK4007","ACRS"],"gpt_icon":0},{"id":"2486705257","title":"单月超6亿美元，医药企业IPO规模重返疫情前水平","url":"https://stock-news.laohu8.com/highlight/detail?id=2486705257","media":"财通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486705257?lang=zh_cn&edition=full","pubTime":"2024-11-25 17:34","pubTimestamp":1732527240,"startTime":"0","endTime":"0","summary":"今年以来，生物医药领域已经有30家公司IPO上市，累计融资规模超40.49亿美元，其中不乏CG Oncology、Kyverna Therapeutics等IPO规模超3亿美元的公司。在多肽类PTH1R激动剂领域，阿斯利康以总价18亿美元收购AmolytPharma，获得了处于临床3期的PTH1R激动剂eneboparatide，目前该疗法已经获得了FDA快速通道认定，另一家药企AscendisPharma的Yorvipath获得FDA批准上市，用于治疗成人慢性甲状旁腺功能减退。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2024-11-25/doc-incxhqmk8147031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4599","BK4539","BK4082","SEPN","BDMD","TQQQ","BK4200","BK4561","BK4139","BK4007","PSQ","QID","QLD",".IXIC","GPCR","SYRS","SQQQ","OMGA","AVTE","CAMP","BK4020","ASO","UPB","TSLP","GLYC","NQmain","MNQmain","APGE"],"gpt_icon":1},{"id":"2485388265","title":"金十数据整理：每日美股市场要闻速递（11月22日 周五）","url":"https://stock-news.laohu8.com/highlight/detail?id=2485388265","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485388265?lang=zh_cn&edition=full","pubTime":"2024-11-22 21:54","pubTimestamp":1732283683,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["WCT","LU1008478684.HKD","TSLA","TCEHY","AMGN","COIN","ESTC","GOOGL","LU0672654240.SGD","HTCD.SI","159526","LU0310799852.SGD","LU0238689110.USD","161631","LU0308772762.SGD","300024","00700","GOOG","IE00BFXG0V08.USD","LLY","RDDT","IE00B3SWFQ91.USD","CMA","LU0326950275.SGD","BK4550","AAPL","LU1023059063.AUD","LU1224444064.USD","IE00B031HW06.USD","LU0061477393.USD","LU1803068623.USD","LU0385154629.USD","EH","LU0553294199.USD","AZN","LU1868837300.USD","IE00B4R5TH58.HKD","LU1839511570.USD","LU2237443895.HKD","LU0384037296.USD","IE00B5TLWC47.USD","FFIE","80700","IE0031814852.USD","LU0634319403.HKD","LU0080751232.USD","LU0648948544.HKD","LU2275660780.HKD","TSLP"],"gpt_icon":0},{"id":"2485792250","title":"阿斯利康(AZN.US)、安进(AMGN.US)皮下注射TSLP 单抗国内报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2485792250","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485792250?lang=zh_cn&edition=full","pubTime":"2024-11-22 21:12","pubTimestamp":1732281156,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11 月 22 日，CDE 官网显示，阿斯利康和安进联合递交了 TSLP 单抗特泽利尤单抗注射液的上市申请。这些患者的 TSLP 表达增加，并且与疾病严重程度相关。阻断 TSLP 可能会阻止免疫细胞释放促炎细胞因子，从而预防病情恶化并改善疾病控制。研究表明，针对气道上皮释放的 TSLP 可能是未来治疗下呼吸道疾病的潜在方法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1214941.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TSLP","IE00BJT1NW94.SGD","BK4566","SG9999001440.SGD","LU0122379950.USD","LU2236285917.USD","BK4568","BK4599","LU1571399168.USD","LU0289739699.SGD","BK4533","IE00B2B36J28.USD","LU1061106388.HKD","LU1983299246.USD","LU0868494617.USD","BK4585","BK4139","LU2242652126.USD","LU2242646821.SGD","LU0109394709.USD","LU0320765992.SGD","AMGN","LU1829250122.USD","LU2456880835.USD","LU1023059063.AUD","LU2112291526.USD","LU0058720904.USD","IE0009355771.USD","LU1057294990.SGD","LU2417539215.USD","AZN","IE00BFTCPJ56.SGD","LU2462157665.USD","IE00BJJMRZ35.SGD","IE0002141913.USD","BK4581","IE00B4R5TH58.HKD","LU0889565916.HKD","BK4534","BK4588","BK4007"],"gpt_icon":0},{"id":"2485234953","title":"礼来替尔泊肽、阿斯利康和安进TSLP 单抗国内报上市，默沙东抗肿瘤新药国内获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2485234953","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2485234953?lang=zh_cn&edition=full","pubTime":"2024-11-22 17:17","pubTimestamp":1732267045,"startTime":"0","endTime":"0","summary":"阿斯利康和安进的TSLP 单抗国内报上市今日，CDE 官网显示，阿斯利康和安进联合递交了 TSLP 单抗特泽利尤单抗注射液的上市申请。这些患者的 TSLP 表达增加，并且与疾病严重程度相关。阻断 TSLP 可能会阻止免疫细胞释放促炎细胞因子，从而预防病情恶化并改善疾病控制。它是一款 first-in-class TSLP单抗，此前已在美国、欧盟、日本地区获批上市，用于治疗哮喘。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122173722abd7037e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241122173722abd7037e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0823416689.USD","LU0289739699.SGD","SG9999014575.USD","LU1430594728.SGD","LU0122379950.USD","LU0456855351.SGD","LU1366192091.USD","BK4007","LU1623119135.USD","SG9999001440.SGD","LU1868836757.USD","LU2462157665.USD","IE00B1BXHZ80.USD","SGXZ57979304.SGD","LU1983299246.USD","LU0070302665.USD","LU0203202063.USD","TSLP","LLY","BK4533","SG9999014559.SGD","SG9999018865.SGD","LU1934455194.USD","BK4581","LU1057294990.SGD","LU1868836591.USD","LU2491050154.USD","LU0106261372.USD","LU1127390331.HKD","AMGN","LU2237443895.HKD","IE00B4R5TH58.HKD","LU1291159041.SGD","LU0466842654.USD","LU2242646821.SGD","LU2361045086.USD","LU0672654240.SGD","LU2264538146.SGD","LU2468319806.SGD","IE00BFTCPJ56.SGD","LU1037948541.HKD","LU1934455863.HKD","LU2602419157.SGD","MRK","LU1551013342.USD","LU0354030438.USD","AZN","LU2324357040.USD","BK4585","IE00BLSP4239.USD"],"gpt_icon":1},{"id":"2481106756","title":"和铂医药向国家药品监督管理局递交HBM9378/SKB378治疗慢性阻塞性肺疾病的临床试验申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2481106756","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481106756?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:42","pubTimestamp":1731058920,"startTime":"0","endTime":"0","summary":"其较长的半衰期优化设计和优秀的理化性质使HBM9378/SKB378在给药和剂型方面拥有潜在优势。我们对HBM9378/SKB378的前景充满信心，并相信这一新型疗法能够满足慢性阻塞性肺疾病患者的多样化需求。目前，公司已在中国完成了HBM9378/SKB378针对中重度哮喘治疗的I期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4551688_ZH51688_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["02142","TSLP","BK1574","BK1583","BK1161"],"gpt_icon":0},{"id":"2481402231","title":"和铂医药-B(02142)：抗TSLP全人源单克隆抗体(HBM9378/SKB378)慢性阻塞性肺疾病新药临床申请提交国家药品监督管理局","url":"https://stock-news.laohu8.com/highlight/detail?id=2481402231","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481402231?lang=zh_cn&edition=full","pubTime":"2024-11-08 17:10","pubTimestamp":1731057030,"startTime":"0","endTime":"0","summary":"和铂医药-B(02142)发布公告，集团已向国家药品监督管理局提交了一项 \nHBM...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_17.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1208555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1161","TSLP","BK1583","02142"],"gpt_icon":0},{"id":"2478718663","title":"Upstream Bio补办敲钟仪式：市值12亿美元 OrbiMed是大股东","url":"https://stock-news.laohu8.com/highlight/detail?id=2478718663","media":"雷递网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478718663?lang=zh_cn&edition=full","pubTime":"2024-10-27 10:00","pubTimestamp":1729994427,"startTime":"0","endTime":"0","summary":"临床阶段生物技术公司Upstream Bio（股票代码为：“UPB”）日前补办纳斯达克敲钟上市，募资总额为2.55亿美元。截至今日收盘，Upstream Bio股价为25.06美元，市值为12.24亿美元。","market":"hk","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20241027/6386562002026915372833937.png","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20241027/6386562002026915372833937.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.leinews.com/n28046/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["TSLP"],"gpt_icon":0},{"id":"2462143721","title":"和铂医药公布2024年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2462143721","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462143721?lang=zh_cn&edition=full","pubTime":"2024-08-28 17:51","pubTimestamp":1724838660,"startTime":"0","endTime":"0","summary":"中国苏州、美国马萨诸塞州剑桥和荷兰鹿特丹2024年8月28日 /美通社/ -- 和铂医药，一家专注于肿瘤及免疫领域创新抗体疗法发现、开发及商业化的全球生物医药公司，今日公布截至2024年6月30日的中期业绩。2023年3月，公司宣布其III期临床试验取得积极研究结果。2024年1月，普鲁苏拜单抗联合PD-1抑制剂治疗晚期结直肠癌的受试者开始入组。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4493199_ZH93199_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4590","BK4218","BK4585","BK4588","L","TSLP","LU0053666078.USD","02142","BK4107","BK1583","NEN","BK4205","BK4233","BK4181","BK4006","BK1161","HCC","BK1574","PK"],"gpt_icon":0},{"id":"2462740963","title":"中国生物制药(01177)：“TQC3721(PDE3/4抑制剂)”、“TQC2731(TSLP单抗)”共3项研究数据在ERS 2024公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2462740963","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2462740963?lang=zh_cn&edition=full","pubTime":"2024-08-26 16:51","pubTimestamp":1724662295,"startTime":"0","endTime":"0","summary":"中国生物制药(01177)发布公告，集团开发的两款创新药“TQC3721(PDE3...","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_27.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1170547.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["TSLP","01177","BK1515","BK1191","BK1521","BK1589"],"gpt_icon":0},{"id":"2453078842","title":"【辉瑞(PFE.US)两款三抗在中国启动2期临床 治疗特应性皮炎】智通财经APP获悉，7月23日，中国药物临床试验登记与信息公示平台显示，辉瑞(PFE.","url":"https://stock-news.laohu8.com/highlight/detail?id=2453078842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453078842?lang=zh_cn&edition=full","pubTime":"2024-07-24 16:31","pubTimestamp":1721809919,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["SG9999001176.SGD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","LU0170899867.USD","BK4592","03347","IE0002270589.USD","BK1141","LU1023059063.AUD","LU1894683264.USD","BK4588","SG9999011175.SGD","SG9999013999.USD","LU0868494617.USD","SG9999003800.SGD","LU0234572021.USD","BK4533","LU1883839398.USD","TSLP","SG9999002224.SGD","BK4585","IE00BLSP4239.USD","LU1057294990.SGD","IE00B19Z3581.USD","LU1066051498.USD","LU1066053197.SGD","LU0289739699.SGD","SG9999002232.USD","LU0456855351.SGD","BK1576","SG9999001176.USD","LU0058720904.USD","BK4568","BK4534","BK1583","BK4007","LU0122379950.USD","BK4581","LU0321505439.SGD","LU1894683348.USD","SGXZ57979304.SGD","LU0321505868.SGD","PFE","BK4550","IE00BBT3K403.USD"],"gpt_icon":0},{"id":"2443939986","title":"6月13日中国国家药监局药品审评中心（CDE）官网公示辉瑞两款1类新药获批临床二者均拟开发治疗成人中度至重度特应性皮炎。根据辉瑞公开资料这两款产品均为三特异性抗体为该公司炎症和免疫管线中的新分子实体。","url":"https://stock-news.laohu8.com/highlight/detail?id=2443939986","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443939986?lang=zh_cn&edition=full","pubTime":"2024-06-15 10:55","pubTimestamp":1718420112,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4581","LU0122379950.USD","TSLP","IE00BBT3K403.USD","SG9999002232.USD","LU0289739699.SGD","SG9999001176.USD","SGXZ57979304.SGD","LU0058720904.USD","BK4568","LU1066053197.SGD","IE0002270589.USD","SG9999013999.USD","LU0321505868.SGD","SG9999011175.SGD","BK4017","PFE","BK4585","CDE","LU1023059063.AUD","BK4533","LU0234572021.USD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","SG9999002224.SGD","SG9999003800.SGD","LU1066051498.USD","BK4550","LU0321505439.SGD","BK4592","BK4007","LU0868494617.USD","LU1057294990.SGD","SG9999001176.SGD","LU0456855351.SGD","IE00BLSP4452.SGD","BK4588","LU0170899867.USD","IE00BLSP4239.USD","BK4534"],"gpt_icon":0},{"id":"2443295933","title":"【辉瑞(PFE.US)两款三抗新药在中国获批临床】智通财经APP获悉，6月13日，中国国家药监局药品审评中心（CDE）官网公示，辉瑞(PFE.","url":"https://stock-news.laohu8.com/highlight/detail?id=2443295933","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2443295933?lang=zh_cn&edition=full","pubTime":"2024-06-15 09:39","pubTimestamp":1718415541,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4581","LU0170899867.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","CDE","BK4017","BK4568","SG9999011175.SGD","BK4533","LU0456855351.SGD","SGXZ57979304.SGD","LU0868494617.USD","LU0122379950.USD","LU0234572021.USD","TSLP","IE0002270589.USD","SG9999003800.SGD","BK4592","BK4588","BK4550","PFE","BK4534","LU0321505439.SGD","LU1066051498.USD","SG9999001176.SGD","LU0289739699.SGD","LU0058720904.USD","BK4585","SG9999013999.USD","LU1057294990.SGD","IE00BLSP4239.USD","IE00BLSP4452.SGD","LU0321505868.SGD","BK4007","SG9999002224.SGD","LU1023059063.AUD","IE00BBT3K403.USD","IE00B19Z3581.USD","SG9999001176.USD","SG9999002232.USD"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0007},{"period":"1month","weight":0.1994},{"period":"3month","weight":0.361},{"period":"6month","weight":0.5836},{"period":"1year","weight":0.1311},{"period":"ytd","weight":0.1433}],"compareEarnings":[{"period":"1week","weight":-0.0221},{"period":"1month","weight":0.0006},{"period":"3month","weight":0.0397},{"period":"6month","weight":0.0851},{"period":"1year","weight":0.2499},{"period":"ytd","weight":0.243}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"exchange":"AMEX","name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","nameEN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Kurv Yield Premium Strategy Tesla (TSLA) ETF,TSLP,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票老虎,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票老虎国际,Kurv Yield Premium Strategy Tesla (TSLA) ETF行情,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票行情,Kurv Yield Premium Strategy Tesla (TSLA) ETF股价,Kurv Yield Premium Strategy Tesla (TSLA) ETF股市,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票价格,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票交易,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票购买,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}